Risk factor
Strong trading liquidity
Profitability factor
Favourable analyst view
About
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of LEGN is 79 and suggests 160% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell